Division of Cardiology, University of British Columbia, Vancouver, Canada.
BC Centre for Improved Cardiovascular Health, Vancouver, Canada.
Heart. 2018 Feb;104(3):237-243. doi: 10.1136/heartjnl-2017-311638. Epub 2017 Jul 26.
Implantable cardioverter-defibrillators (ICDs) reduce risk of death in select populations, but are also associated with harms. We aimed to characterise long-term complications and reoperation rate.
We assessed the rate, cumulative incidence and predictors of long-term reoperation and survival using a prospective, multicentre registry serving British Columbia in Canada, a universal single payer healthcare system with 4.5 million residents. 3410 patients (mean 63.3 years, 81.7% male) with new primary (n=1854) or secondary prevention (n=1556) ICD implant from 2003 to 2012 were followed for a median of 34 months (single chamber n=1069, dual chamber n=1905, biventricular n=436). Independent predictors of adverse outcomes were defined using Cox regression models.
The overall reoperation rate was 12.0% per patient-year, and less for single vs dual vs biventricular ICDs (9.1% vs 12.5% vs 17.8% per patient-year, respectively). The Kaplan-Meier complication estimates (excluding generator end of life) at 1, 3 and 5 years were respectively: single chamber 10.2%, 16.2% and 21.6%; dual 11.7%, 19.1% and 27.4% and biventricular 15.9%, 22.2% and 24.7%. Cardiac resynchronisation therapy had the highest rate of early lead complications, but lower long-term need for upgrade. Device complexity, age and atrial fibrillation were key determinants of complications. Overall mortality at 1, 3 and 5 years was 5.4%, 17.4% and 32.7%, respectively. In younger patients, observed 5-year survival approached the expected survival in the general population (relative survival ratio=0.96 (0.90-0.98)). With increasing age, observed survival steadily declined relative to expected.
In a prospective registry capturing all procedures, complication and reoperation rates following de novo ICD implantation were high. Shared decision making must carefully consider these factors.
植入式心脏复律除颤器 (ICD) 可降低特定人群的死亡风险,但也与危害有关。我们旨在描述长期并发症和再次手术率。
我们使用前瞻性、多中心注册中心评估了长期再次手术和生存的发生率、累积发生率和预测因素,该注册中心服务于加拿大不列颠哥伦比亚省,该省实行全民单一支付者医疗保健系统,拥有 450 万居民。2003 年至 2012 年间,3410 名患有新原发性(n=1854)或二级预防(n=1556)ICD 植入的患者(平均年龄 63.3 岁,81.7%为男性)接受了中位 34 个月的随访(单腔 n=1069,双腔 n=1905,双心室 n=436)。使用 Cox 回归模型定义不良结局的独立预测因素。
总体再次手术率为每患者年 12.0%,单腔 ICD 低于双腔 ICD 和双心室 ICD(每患者年分别为 9.1%、12.5%和 17.8%)。1 年、3 年和 5 年的 Kaplan-Meier 并发症估计值(不包括发电机寿命终结)分别为:单腔 10.2%、16.2%和 21.6%;双腔 11.7%、19.1%和 27.4%和双心室 15.9%、22.2%和 24.7%。心脏再同步治疗的早期导线并发症发生率最高,但长期升级需求较低。设备复杂性、年龄和心房颤动是并发症的关键决定因素。1 年、3 年和 5 年的总死亡率分别为 5.4%、17.4%和 32.7%。在年轻患者中,观察到的 5 年生存率接近一般人群的预期生存率(相对生存率比=0.96(0.90-0.98))。随着年龄的增长,观察到的生存率相对于预期生存率稳步下降。
在一项前瞻性注册研究中,记录了 ICD 植入后新发并发症和再次手术的发生率较高。决策必须仔细考虑这些因素。